{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:00:20Z","timestamp":1790085620459,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 21 1485 Pj (VT)"],"award-info":[{"award-number":["CAN 21 1485 Pj (VT)"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["23 2645 PjF 01H (AO)"],"award-info":[{"award-number":["23 2645 PjF 01H (AO)"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-00556 (AO)"],"award-info":[{"award-number":["2022-00556 (AO)"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biopha.2026.119908","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:56:36Z","timestamp":1788580596000},"page":"119908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Experimental radiotherapy with the gastrin-releasing peptide receptor (GRPR) antagonist [177Lu]Lu-AU-SAR-M1 in a prostate cancer murine model using reduced-frequency dosing"],"prefix":"10.1016","volume":"203","author":[{"given":"Karim","family":"Obeid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5895-8500","authenticated-orcid":false,"given":"Mark","family":"Konijnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7699-5719","authenticated-orcid":false,"given":"Ekaterina","family":"Bezverkhniaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1123-2486","authenticated-orcid":false,"given":"Theodosia","family":"Maina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6028-9112","authenticated-orcid":false,"given":"Berthold A.","family":"Nock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Tolmachev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0617-3936","authenticated-orcid":false,"given":"Panagiotis","family":"Kanellopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6120-2683","authenticated-orcid":false,"given":"Anna","family":"Orlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119908_bib1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1210\/er.2002-0007","article-title":"Peptide receptors as molecular targets for cancer diagnosis and Therapy","volume":"24","author":"Reubi","year":"2003","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.biopha.2026.119908_bib2","first-page":"1152","article-title":"Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation","volume":"59","author":"Markwalder","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119908_bib3","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119908_bib4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00259-004-1476-2","article-title":"High expression of peptide receptors as a novel target in gastrointestinal stromal tumours","volume":"31","author":"Reubi","year":"2004","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.biopha.2026.119908_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0167-0115(00)00114-2","article-title":"The presence of receptors for bombesin\/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers","volume":"90","author":"Sun","year":"2000","journal-title":"Regul. Pept."},{"key":"10.1016\/j.biopha.2026.119908_bib6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.brainresbull.2010.02.014","article-title":"Gastrin-releasing peptide receptor content in human glioma and normal brain","volume":"82","author":"Flores","year":"2010","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.biopha.2026.119908_bib7","article-title":"The gastrin-releasing peptide receptor in oncology: a comprehensive review of recent advances in targeted radionuclide theranostics","volume":"16","author":"Yang","year":"2026","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119908_bib8","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.2967\/jnumed.124.269444","article-title":"A Vision for Gastrin-Releasing Peptide Receptor Targeting for Imaging and Therapy: Perspective from Academia and Industry","volume":"66","author":"Morgat","year":"2025","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biopha.2026.119908_bib9","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41571-025-01069-z","article-title":"The molecular blueprint of targeted radionuclide therapy","volume":"22","author":"Primac","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119908_bib10","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.7150\/thno.107963","article-title":"Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during 177Lu\/225Ac treatment in neuroendocrine tumors and metastatic prostate cancer","volume":"15","author":"Dadgar","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2026.119908_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00006676-199601000-00004","article-title":"Expression and characterization of gastrin-releasing peptide receptor in normal and cancerous pancreas","volume":"12","author":"Hajri","year":"1996","journal-title":"Pancreas"},{"key":"10.1016\/j.biopha.2026.119908_bib12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/(SICI)1097-0045(20000301)42:4<295::AID-PROS7>3.0.CO;2-B","article-title":"Presence of receptors for bombesin\/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers","volume":"42","author":"Sun","year":"2000","journal-title":"Prostate"},{"key":"10.1016\/j.biopha.2026.119908_bib13","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.3390\/cancers13225766","article-title":"Radiolabeled bombesin analogs","volume":"13","author":"Mansi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119908_bib14","doi-asserted-by":"crossref","first-page":"10662","DOI":"10.1073\/pnas.88.23.10662","article-title":"CD10\/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung","volume":"88","author":"Shipp","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2026.119908_bib15","doi-asserted-by":"crossref","unstructured":"Suresh A., Rajan S., Pomper M.G., Rowe S.P., Banerjee S.R. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer. Semin Nucl Med. 23;53:663-686. https:\/\/dx.doi.org\/10.1053\/j.semnuclmed.2023.06.007.","DOI":"10.1053\/j.semnuclmed.2023.06.007"},{"key":"10.1016\/j.biopha.2026.119908_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00259-019-04504-3","article-title":"First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer","volume":"47","author":"Kurth","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.biopha.2026.119908_bib17","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2967\/jnumed.125.270411","article-title":"Phase 1 Study of [177Lu]Lu-NeoB in Patients with Advanced Solid Tumors Overexpressing Gastrin-Releasing Peptide Receptor: Preliminary Safety and Dosimetry Results","volume":"67","author":"Mittra","year":"2026","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biopha.2026.119908_bib18","unstructured":"Prostate cancer and GRPR. https:\/\/clinicaltrials.gov\/search?cond=Prostat%20Cancer&term=GRPR&page=1&viewType=Card (accessed 5 May 202)."},{"key":"10.1016\/j.biopha.2026.119908_bib19","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1002\/ijc.32401","article-title":"Trastuzumab co-treatment improves survival of mice with PC-3 prostate cancer xenografts treated with GRPR antagonist [177Lu]Lu-DOTAGA-PEG2-RM26","volume":"145","author":"Mitran","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2026.119908_bib20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1034\/j.1399-3011.1999.00028.x","article-title":"Syntheses and biological activities of potent bombesin receptor antagonists","volume":"53","author":"Llinares","year":"1999","journal-title":"J. Pept. Res."},{"key":"10.1016\/j.biopha.2026.119908_bib21","doi-asserted-by":"crossref","first-page":"15695","DOI":"10.1016\/S0021-9258(18)55454-5","article-title":"Des-Met carboxylterminally modified analogues of bombesin function as potent bombesin receptor antagonists, partial agonists, or agonists","volume":"265","author":"Wang","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119908_bib22","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3390\/biom13071134","article-title":"Preclinical characterization of a stabilized GRPR antagonist for targeted cancer theranostics","volume":"13","author":"Abouzayed","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2026.119908_bib23","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3390\/pharmaceutics16040513","article-title":"GRPR-antagonists carrying DOTAGA-chelator via positively-charged linkers: Perspectives for prostate cancer theranostics","volume":"16","author":"Obeid","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119908_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s41181-024-00242-6","article-title":"Preclinical evaluation of new GRPR antagonists with improved metabolic stability for radiotheranostic use in oncology","volume":"9","author":"Kanellopoulos","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.biopha.2026.119908_bib25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s41181-025-00374-3","article-title":"RM2 and DB15 analogues bearing [177Lu]Lu-DOTAGA via different linkers, as radiotherapeutics: a head-to-head comparative study","volume":"10","author":"Kanellopoulos","year":"2025","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.biopha.2026.119908_bib26","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3390\/pharmaceutics17101323","article-title":"Phase I clinical study with the GRPR-antagonist [99mTc]Tc-DB8 for SPECT imaging of prostate cancer: Does the injected peptide mass make a difference?","volume":"17","author":"Orlova","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119908_bib27","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.3390\/cancers14235792","article-title":"A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients","volume":"14","author":"Becx","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119908_bib28","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu labeled PSMA targeted radioligand therapy (177Lu PSMA RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.biopha.2026.119908_bib29","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2967\/jnumed.110.075101","article-title":"Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention","volume":"51","author":"Vegt","year":"2010","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biopha.2026.119908_bib30","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2967\/jnumed.112.112169","article-title":"Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin","volume":"54","author":"Dumont","year":"2013","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biopha.2026.119908_bib31","doi-asserted-by":"crossref","DOI":"10.1007\/s11307-023-01851-4","article-title":"The Balance Between the Therapeutic Efficacy and Safety of [(177)Lu]Lu-NeoB in a Preclinical Prostate Cancer Model","volume":"26","author":"Verhoeven","year":"2024","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.biopha.2026.119908_bib32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1021\/acsptsci.5c00491","article-title":"Preclinical evaluation of 177Lu-labeled gastrin-releasing peptide receptor antagonist and prostate cancer treatment with monotherapy and in combination with everolimus","volume":"9","author":"Kumar","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.biopha.2026.119908_bib33","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","article-title":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands","volume":"49","author":"Sj\u00f6green Gleisner","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.biopha.2026.119908_bib34","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00259-018-3945-z","article-title":"Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity","volume":"45","author":"Garske-Rom\u00e1n","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.biopha.2026.119908_bib35","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.3390\/ijms26146968","article-title":"Effects of targeted radionuclide therapy on cancer cells beyond the ablative radiation dose","volume":"26","author":"Ferro-Flores","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119908_bib36","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.3390\/cancers15092592","article-title":"Tumor sink effect with prostate-specific membrane antigen-targeted theranostics in patients with metastatic castration-resistant prostate cancer: intra-individual evaluations","volume":"15","author":"Burgard","year":"2023","journal-title":"Cancers"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:07:07Z","timestamp":1790082427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226009443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"alternative-id":["S0753332226009443"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119908","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experimental radiotherapy with the gastrin-releasing peptide receptor (GRPR) antagonist [177Lu]Lu-AU-SAR-M1 in a prostate cancer murine model using reduced-frequency dosing","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119908","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119908"}}